Skip to main content
IMAGION BIOSYSTEMS LIMITED logo

IMAGION BIOSYSTEMS LIMITED — Investor Relations & Filings

Ticker · IBX ISIN · AU000000IBX6 ASX Professional, scientific and technical activities
Open in API
Filings indexed 659 across all filing types
Latest filing 2023-04-12 Investor Presentation
Country AU Australia
Listing ASX IBX

About IMAGION BIOSYSTEMS LIMITED

https://imagionbiosystems.com/

Imagion Biosystems Limited is a medical technology company specializing in the development of advanced diagnostic imaging solutions. The company's proprietary MagSense technology utilizes superparamagnetic iron oxide nanoparticles to detect specific cancer cells non-invasively. By functionalizing these nanoparticles with targeting antibodies, the system can identify the presence and location of malignancies, such as HER2-positive breast cancer, using highly sensitive magnetic sensors. This approach aims to provide a safer, more accurate alternative to traditional biopsy and imaging methods by eliminating the need for ionizing radiation or radioactive tracers. The technology is designed to improve clinical decision-making through earlier detection and better staging of diseases, ultimately enhancing patient outcomes in oncology.

Recent filings

Filing Released Lang Actions
Imagion Biosystems April 2023 Investor Newsletter 7 pages 689.4KB
Investor Presentation Classification · 95% confidence The document is titled 'Imagion Biosystems April 2023 Investor Newsletter' and is described as an investor newsletter providing updates on company developments, CEO message, commercial partner outreach, new IP and analytics efforts, upcoming events, and media coverage. It is a newsletter format rather than a formal financial report. There are no detailed financial statements or comprehensive financial performance data included. The document is about company updates and investor communication but does not contain quarterly or annual financial results or detailed management analysis. It is not an earnings release, annual report, or interim report. The document is longer than 5,000 characters but is clearly a newsletter, which fits best under the category of Investor Presentation (IP) as it is a detailed presentation for investors focusing on company strategy, developments, and market position rather than a formal report or announcement. Therefore, the most appropriate classification is Investor Presentation (IP).
2023-04-12 English
Notification regarding unquoted securities - IBX 9 pages 32.3KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Notification of Issue, Conversion or Payment up of Unquoted Equity Securities' and details the issuance of unquoted securities under an employee incentive scheme by Imagion Biosystems Limited. It includes specifics such as security types, issue dates, quantities, and references to ASX listing rules. There is no financial performance data, management discussion, or earnings information. The document is an announcement of securities issuance rather than a full financial report or regulatory certification. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes.
2023-04-10 English
Notification of cessation of securities - IBX 5 pages 26.3KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the lapse of certain options and securities for IMAGION BIOSYSTEMS LIMITED. It provides specific information about securities that have ceased, including ASX security codes, number of securities ceased, reasons for cessation, and updated issued capital figures. The document is a formal announcement about changes in the company's issued capital due to securities lapsing. It does not contain financial statements, management discussion, or audit information. It is not a report but an announcement of changes in securities. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes such as cessation or lapse of securities.
2023-04-10 English
Notice to IBXOA Option Holders 3 pages 202.2KB
Share Issue/Capital Change Classification · 95% confidence The document is a notice to holders of listed options (ASX: IBXOA) regarding the expiry and exercise of these options. It provides details on the expiry date, exercise price, trading cessation date for the options, and instructions for exercising or selling the options. There is no financial statement, earnings data, or management discussion. The document is an announcement related to capital instruments (options) and their expiry, which fits the category of Share Issue/Capital Change announcements rather than a full financial report or other categories. The document length is about 5,194 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2023-03-27 English
Imagion to proceed to file an IND following FDA feedback 2 pages 119.1KB
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 27 March 2023 from Imagion Biosystems Limited providing an update on development plans for its MagSense HER2 Imaging Agent following feedback from the FDA. It discusses plans to file an Investigational New Drug (IND) application and outlines upcoming activities related to clinical trials and manufacturing. The document does not contain financial statements, detailed financial performance data, or comprehensive management analysis. It is an update on regulatory and development progress rather than a financial report or detailed investor presentation. The length is under 5,000 characters and it serves as a progress update and regulatory communication. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-03-26 English
Entitlement Offer - Extension of Closing Date 2 pages 132.4KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Imagion Biosystems Limited regarding an extension of the closing date for a non-renounceable entitlement offer, which is a capital raising activity. It details the revised timetable for the offer, including record date, opening date, closing date, and issue date of new shares. There is no financial report, earnings data, or management discussion present. The content focuses on fundraising and capital structure changes. Therefore, this fits the category of Capital/Financing Update (CAP). The document length is 3633 characters, which is consistent with an announcement rather than a full report.
2023-03-26 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.